Primary Care & Population Sciences, University of Southampton, Aldermoor Health Centre, Southampton, United Kingdom.
Institute of Psychology Health and Society, University of Liverpool, Liverpool, United Kingdom.
Ann Fam Med. 2019 Jan;17(1):52-60. doi: 10.1370/afm.2336.
We aimed to determine the effectiveness of interventions to manage antidepressant discontinuation, and the outcomes for patients.
We conducted a systematic review with narrative synthesis and meta-analysis of studies published to March 2017. Studies were eligible for inclusion if they were randomized controlled trials, quasi-experimental studies, or observational studies assessing interventions to facilitate discontinuation of antidepressants for depression in adults. Our primary outcomes were antidepressant discontinuation and discontinuation symptoms. Secondary outcomes were relapse/recurrence; quality of life; antidepressant reduction; and sexual, social, and occupational function.
Of 15 included studies, 12 studies (8 randomized controlled trials, 2 single-arm trials, 2 retrospective cohort studies) were included in the synthesis. None were rated as having high risk for selection or detection bias. Two studies prompting primary care clinician discontinuation with antidepressant tapering guidance found 6% and 7% of patients discontinued, vs 8% for usual care. Six studies of psychological or psychiatric treatment plus tapering reported cessation rates of 40% to 95%. Two studies reported a higher risk of discontinuation symptoms with abrupt termination. At 2 years, risk of relapse/recurrence was lower with cognitive behavioral therapy plus taper vs clinical management plus taper (15% to 25% vs 35% to 80%: risk ratio = 0.34; 95% CI, 0.18-0.67; 2 studies). Relapse/recurrence rates were similar for mindfulness-based cognitive therapy with tapering and maintenance antidepressants (44% to 48% vs 47% to 60%; 2 studies).
Cognitive behavioral therapy or mindfulness-based cognitive therapy can help patients discontinue antidepressants without increasing the risk of relapse/recurrence, but are resource intensive. More scalable interventions incorporating psychological support are needed.
本研究旨在评估管理抗抑郁药停药的干预措施的效果,以及对患者结局的影响。
我们对截至 2017 年 3 月发表的研究进行了系统评价,采用叙述性综述和荟萃分析。纳入研究需为评估促进成年人抗抑郁药停药以治疗抑郁症的干预措施的随机对照试验、准实验研究或观察性研究。主要结局为抗抑郁药停药和停药症状。次要结局为复发/再发;生活质量;抗抑郁药剂量减少;以及性功能、社交功能和职业功能。
在纳入的 15 项研究中,有 12 项研究(8 项随机对照试验、2 项单臂试验、2 项回顾性队列研究)被纳入综述。无研究被评为存在选择或检测偏倚高风险。两项研究通过提示初级保健临床医生在抗抑郁药逐渐减量时停药,发现接受指导逐渐停药的患者中分别有 6%和 7%停药,而常规护理组的停药率为 8%。6 项心理或精神科治疗加逐渐减量的研究报告的停药率为 40%至 95%。两项研究报告称,突然停药与更高的停药症状风险相关。在 2 年时,认知行为疗法加逐渐减量与临床管理加逐渐减量相比,复发/再发的风险较低(15%至 25%比 35%至 80%:风险比=0.34;95%置信区间,0.18-0.67;2 项研究)。逐渐减量的正念认知疗法与维持抗抑郁药的复发/再发率相似(44%至 48%比 47%至 60%;2 项研究)。
认知行为疗法或正念认知疗法可以帮助患者在不增加复发/再发风险的情况下停止使用抗抑郁药,但需要投入更多资源。需要采取更具可扩展性的干预措施,纳入心理支持。